• Doing patsyentok c leyomyomoy uterus. Conservative treatment methods (Overview of the Canadian SOGC Clinical Manual)

Doing patsyentok c leyomyomoy uterus. Conservative treatment methods (Overview of the Canadian SOGC Clinical Manual)

HEALTH OF WOMAN. 2017.5(121):86–91

Zhylka N. Ya.
National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

Changes in the pathogenesis of cancer myomы, namely dopolnenye of existing theories Reduction Quantity women in modern childbirth and menstruation Quantity yzbыtochnoe allows us except hormonalnыh methods of treatment of uterine myomы dovolno эffektyvno Apply selektyvnыe modulyatorы progesterone receptors.

Key words: leiomyoma of the uterus, konservatyvnoe treatment, selective progesterone receptor modulator.

References

1. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. 2003. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–7. https://doi.org/10.1067/mob.2003.99

2. Munro MG, Critchley HO, Broder MS, Fraser IS. 2011. The FIGO Classi cation System (“PALM­COEIN”) for causes of abnormal uterine bleeding m non­gravid women m the reproductive years, including guidelines for clinical investigation. IntJ Gynaecol Obstet 113:3–13. https://doi.org/10.1016/j.ijgo.2010.11.011; PMid:21345435

3. Bulun SE. 2013. Uterine broids. N Engl J Med 369:1344–55. https://doi.org/10.1056/NEJMra1209993; PMid:24088094

4. Flake GP, Andersen J, Dixon D. 2003. Etiology and pathophysiology of uterine leiomyomas; a review. Environ Health Perspect 111:1037–54. https://doi.org/10.1289/ehp.5787; PMid:12826476 PMCid:PMC1241553

5. Miura S, Khan KN, Kitajima M, Hiraki K, Monyama S, Masuzaki H et al. 2006. Differential in ltration of macrophages and prostaglandin by different uterine leiomyomas. Hum Reprod 21:2545–54. https://doi.org/10.1093/humrep/del205; PMid:16763009

6. Schwartz LB, Diamond MP, Schwartz PE. 1993. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 168(1;1):180–3.

7. Parker WH, Fu YS, Berek JS. 1994. Uterine sarcoma m patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83:414–8. PMid:8127535

8. Leibsohn S, d’Ablamg G, Mishell DR Jr, Schlaerth JB. 1990. Leiomyosarcoma m a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 162:968­74; discussion 974–6. https://doi.org/10.1016/0002-9378(90)91298-Q

9. Knight J, Falcone T. 2014. Tissue extraction by morcellation: a clinical dilemma. J Mm Invas Gynecol 21:319–20. https://doi.org/10.1016/j.jmig.2014.03.005; PMid:24646445

10. Cantuana GH, Anglioli R, Frost L, Duncan R, Penalver MA. 1998. Comparison of bimanual examination with ultrasound before hysterectomy for uterine leiomyoma. Obstet Gynecol 92:109–12. https://doi.org/10.1016/S0029-7844(98)00131-8

11. Farquhar C, Ekeroma A, Furness S, Arroll B. 2003. A systematic review of transvagmal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding m premenopausal women. Acta Obstet Gynecol Scand 82:493–504. https://doi.org/10.1034/j.1600-0412.2003.00191.x; PMid:12780419

12. Makns N, Kalmantis K, Startados N, Papadimitriou A, Mantzans G, Antsaklis A. 2007. Three dimensional hysterosonography versus hysteroscopy for the detection of intracavitary uterine abnormalities. IntJ Gynecol Obstet 95:6–9.

13. Bradley LD, Falcone T, Magen AB. 2000. Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clm North Am 27:245–76. https://doi.org/10.1016/S0889-8545(00)80019-4

14. Adusumilli S, Hussain HK, Caoili EM, Weadock WJ, Murray JP, Johnson TD et al. 2006. MRI of sonographically indeterminate adnexal masses. AJR Am J Roentgenol 187:732–40. https://doi.org/10.2214/AJR.05.0905; PMid:16928938

15. Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. 2002. Accuracy of magnetic resonance imaging and transvagmal ultrasonography m the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 186:409–15. https://doi.org/10.1067/mob.2002.121725; PMid:11904599

16. Omary RA, Vasireddy S, Chnsman HB, Ryu RK, Pereles FS, Carr JC et al. 2002. The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine broids. J Vase Interv Radiol 13:1149–53. https://doi.org/10.1016/S1051-0443(07)61957-5

17. Stamatopoulos CP, Mikos T, Grimbizis GF, Dimitnadis AS, Efstratiou I, Stamatopoulos P et al. 2012. Value of magnetic resonance imaging m diagnosis of adenomyosis and myomas of the uterus. J Mm Invas Gynecol 19:620–6. https://doi.org/10.1016/j.jmig.2012.06.003; PMid:22935303

18. Myers ER, Barber MD, Gustilo­Ashby T, Couchman G, Matchar DB, McCrory DC. 2002. Management of uterine leiomyomata: what do we really know Obstet Gynecol 100:8–17. https://doi.org/10.1097/00006250-200207000-00003; https://doi.org/10.1016/S0029-7844(02)02019-7

19. Al­Hendy A, Salama S. 2006. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 12:385–400. https://doi.org/10.1093/humupd/dml015; PMid:16603566

20. Sayed GH, Zakherah MS, El­Nashar SA, Shaaban MM. 2011. A randomized clinical trial of a levonorgestrel­releasmg intrauterine system and a low­dose combined oral contraceptive for broid­related menorrhagia. IntJ Gynaecol Obstet 112:126–30. https://doi.org/10.1016/j.ijgo.2010.08.009; PMid:21092958

21. Maruo T, Ohara N, Yoshida S, Nakabayashi K, Sasaki H, Xu Q et al. 2010. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel­releasmg intrauterine system. Contraception 82:435–41. https://doi.org/10.1016/j.contraception.2010.05.006; PMid:20933117

22. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P, Norgren A et al. 1998. Sex steroid receptors m human myometrium and broids: changes during the menstrual cycle and gonadotropin­releasing hormone treatment. J Clin Endocrinol Metab 11;83:4092–6. https://doi.org/10.1210/jcem.83.11.5287; https://doi.org/10.1210/jc.83.11.4092

23. Magalhaes J, Aldnghi JM, de Lima GR. 2007. Uterine volume and menstrual patterns m users of the levonorgestrel­releasmg intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 75:193–8. https://doi.org/10.1016/j.contraception.2006.11.004; PMid:17303488

24. Verspyck E, Marpeau L, Lucas C. 2000. Leuprorelm depot 3.75 mg versus lynestrenol m the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. Eur J Obstet Gynecol Reprod Biol 89:7–13. https://doi.org/10.1016/S0301-2115(99)00168-2

25. Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. 2013. Progestogens or progestogen­releasing intrauterine systems for uterine broids. Cochrane Database Syst Rev 2:CD008994.

26. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W et al. 1993. An evaluation of the effect of gonadotropin­releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo­controlled, crossover trial. J Clm Endocrinol Metab 76:1217–23. https://doi.org/10.1210/jc.76.5.1217; https://doi.org/10.1210/jcem.76.5.8496313; PMid:8496313

27. Friedman AJ, Daly M, Juneau­Norcross M, Rem MS, Fine C, Gleason R et al. 1993. A prospective, randomized trial of gonadotropm­releasmg hormone agonist plus estrogen­progestm or progestin “addback” regimens for women with leiomyomata uteri. J Clm Endocrinol Metab 76:1439–45. https://doi.org/10.1210/jc.76.6.1439; https://doi.org/10.1210/jcem.76.6.8501148; PMid:8501148

28. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. 1991. Treatment of leiomyomata uteri with leuprolide acetate depot: a double­blind, placebo­controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 77:720–5. PMid:1901638

29. Reissmann T, Diednch K, Comaru­Schally AM, Schally AV. 1994. Introduction of LHRH­antagonists into the treatment of gynaecological disorders. Human Reprod 9:767–9. https://doi.org/10.1093/oxfordjournals.humrep.a138593

30. Britten JL, Malik M, Levy G, Mendoza M, Cathermo WH. 2012. Gonadotropm­releasmg hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production. Fertil Stenl 98:1299–307. https://doi.org/10.1016/j.fertnstert.2012.07.1123; PMid:22901846

31. Panidis D, Vavilis D, Rousso D, Stergiopoulos K, Kalogeropoulos A. 1994. Danazol in uences gonadotropin secretion acting at the hypothalamic level. IntJ Gynaecol Obstet 45:241–6. https://doi.org/10.1016/0020-7292(94)90249-6

32. ACOG Committee on Practice Bulletms­Gynecology. ACOG practice bulletin: surgical alternatives to hysterectomy m the management of leiomyomas. IntJ Gynaecol Obstet. 2001. 73:285–94. https://doi.org/10.1016/S0020-7292(01)00414-3

33. Ke LQ, Yang K, Li J, Li CM. 2009. Danazol for uterine broids. Cochrane Database Syst Rev 3:CD007692.

34. Sumitani H, Shozu M, Segawa T, Murakami K, Yang HJ, Shimada K et al. 2000. In situ estrogen synthesized by aromatase P450 m uterine leiomyoma cells promotes cell growth probably via an autocrme/ mtracrme mechanism. Endocrinology 141:3852–61. https://doi.org/10.1210/endo.141.10.7719; PMid:11014242

35. Song H, Lu D, Navaratnam K, Shi G. 2013. Aromatase inhibitors for uterine broids. Cochrane Database Syst Rev 10:CD009505.

36. Wakelmg AE, Dukes M, Bowler J. 1991. A potent specic pure antiestrogen with clinical potential. Cancer Res 51:3867–73.

37. Donnez J, Hervais Vivancos B, Kudela M, Audebert A, Jadoul P. 2003. A randomized, placebo­controlled, dose­ranging trial comparing fulvestrant with goserelm m premenopausal patients with uterine ­ broids awaiting hysterectomy. Fertil Stenl 79:1380–9. https://doi.org/10.1016/S0015-0282(03)00261-9

38. Dutertre M, Smith CL. 2000. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295:431–7. PMid:11046073

39. Deng L, Wu T, Chen XY, Xie L, Yang J. 2012. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 10:CD005287. https://doi.org/10.1002/14651858.CD005287.pub4

40. Chegini N, Ma C, Tang XM, Williams RS. 2002. Effects of GnRH analogues, Cadd­back steroid therapy, antiestrogen and antiprogestms on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor­beta expression. Mol Hum Reprod 8:1071–8. https://doi.org/10.1093/molehr/8.12.1071; PMid:12468639

41. Maruo T, Ohara N, Wang J, Matsuo H. 2004. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 10:207–20. https://doi.org/10.1093/humupd/dmh019; PMid:15140868

42. Kawaguschi K, Fujn S, Konishi I, Nanbu Y, Nonogaki H, Mon T. 1989. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637–41. https://doi.org/10.1016/S0002-9378(89)80046-8

43. Kawaguschi K, Fujn S, Konishi I, Iwai T, Nanbu Y, Nonogaki H et al. 1991. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki­67 m leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 419:309–15. https://doi.org/10.1007/BF01606522

44. Seagaloff A, Weed JC, Sternberg WH, Parson W. 1949. The progesterone therapy of human uterine leiomyomas. J Clm Endocrinol Metrab 9:1273–91. https://doi.org/10.1210/jcem-9-12-1273; PMid:15399547

45. Friedman AJ, Daly M, Juneau­Norcross M, Gleason R, Rem MS, LeBoff M. 1994. Long­term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen­progestm or progestin ’add­back’ for 2 years. Hum Reprod 9:1618–25. https://doi.org/10.1093/oxfordjournals.humrep.a138762; PMid:7836510

46. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Eiger W. 2005. Selective progesterone receptor modulator development and use m the treatment of leiomyomata and endometriosis. Endocr Rev 26:423–38. https://doi.org/10.1210/er.2005-0001; PMid:15857972

47. Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. 2013. Effects of mifepristone on uterine leiomyoma m premenopausal women: a meta­analysis. Fertil Steril 100:1722–6. https://doi.org/10.1016/j.fertnstert.2013.08.039; PMid:24094421

48. Chabbert­Buffet N, Pmtiaux­Kairis A, Bouchard P. 2007. VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 m a continuous low dose on the hypothalamic­pituitary­ovanan axis and endometrium m normal women: a prospective, randomized, placebo­controlled trial. J Clm Endocrinol Metab 92:3582–9. https://doi.org/10.1210/jc.2006-2816; PMid:17579200

49. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T et al. 2012. Ulipnstal acetate versus placebo for broid treatment before surgery. N Engl J Med 366:409–20. https://doi.org/10.1056/NEJMoa1103182; PMid:22296075

50. Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F et al. 2012. Ulipnstal acetate versus leuprolide acetate for uterine broids. N Engl J Med 366:421–32. https://doi.org/10.1056/NEJMoa1103180; PMid:22296076